Extravasation (paravasation) of chemotherapy drugs – updated recommendations (2020) for standard care in the Czech Republic from the cooperation of the Supportive Care Group of the Czech Society for Oncology, Czech Society for Hematology, Oncology Section of the Czech Nurses Association and the Society for Ports and Permanent Catheters

Česká verze

Authors: prof. MUDr. Vokurka Samuel, Ph.D. ¹; MUDr. Maňásek Viktor ²; Mgr. Hrabánková Navrátilová Darja ³; Mgr. Šípová Simona ¹; MUDr. Šustková Zuzana ⁴; Mgr. Turková Lenka ⁵; Mgr. Fukasová Hajnová Erika ⁶; Sýkorová Zuzana ⁷; PharmDr. Kozáková Šárka; Mba ⁸; Bc. Wintnerová Jitka ⁹
Authors place of work: Onkologická a radioterapeutická klinika LF UK a FN Plzeň ¹; Komplexní onkologické centrum Nový Jičín, Nemocnice Nový Jičín ²; I. interní klinika, klinika hematologie VFN v Praze ³; Interní hematologická a onkologická klinika FN Brno ⁴; Interní hematologická klinika FN Královské Vinohrady, Praha ⁵; Klinika onkologická, FN Ostrava ⁶; Klinika komplexní onkologické péče MOÚ, Brno ⁷; Ústavní lékárna, MOÚ Brno ⁸; Klinika dětské hematologie a onkologie FN Motol, Praha ⁹
Published in the journal: Klin Onkol 2020; 33(5): 390-395
Category: Sdělení
doi: https://doi.org/10.14735/amko2020390

Summary

Backgrounds: Extravasation (paravasation) of chemotherapy drugs is a very significant complication. Preventive and therapeutic interventions reduce the risk of the complication or the extent of its consequences. A working group of authors from expert groups prepared recommendations for standard care.

Purpose: A basic summary of recommended interventions for daily practice, defined on the basis of knowledge from long-term, proven, evidence-based practice or on the consensus opinions of the expert groups representatives.

Results: Preventive measures are essential and include early consideration of long-term venous access devices indications, choice of injection site, venous line control before each chemotherapy drug application, and patient education. The intervention in case of extravasation mainly involves the application of antidotes (DMSO, hyaluronidase, dexrazoxane) and the application of dry cold or heat according to the type of cytostatic drug. Subcutaneous corticosteroids, moist heat or cooling and compression are not recommended.

Conclusion: The recommended procedures contribute to reducing the risk and consequences of extravasation. The range of recommended interventions can be expanded individually depending on individual clinical site policy and needs.

Keywords:

nursing – extravasation – Chemotherapy

Zdroje

1. Vokurka S, Maňásek V, Navrátilová Hrabánková D et al. Extravazace (paravazace) cytostatik – doporučení pro standardní péči v rámci České republiky ze spolupráce Sekce podpůrné léčby České onkologické společnosti ČLS JEP, Onkologické sekce České asociace sester a Společnosti pro porty a permanentní katétry. Klin Onkol 2019; 32 (6): 463–468. doi: 10.14735/amko2019463.

2. Pittiruti M, Capozzoli G. Venous access – a practical textbook. Roma: Antonio Delfino Editore 2018.

3. Maňásek V. Extravazace cytostatik – prevence a doporučené postupy. Klin Onkol 2016; 29 (2): 93–99. doi: doi: 10.14735/amko201693.

4. Charvát J et al. Žilní vstupy – střednědobé a dlouhodobé. Praha: Grada Publishing, 2016.

5. Pérez Fidalgo JA, García Fabregat L, Cervantes A et al. On behalf of the ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol 2012; 23 (Suppl_7): vii167–vii173. doi: 10.1093/annonc/mds294.

6. Mader I. Extravasation of cytotoxic agents: compendium for prevention and management. 2nd ed. New York: Springer 2010.

7. Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008; 58 (6): 323–346. doi: doi: 10.3322/CA.2008.0015.

8. SPC – Doxorubocin Teva 2 mg/ml inf cnc sol 25 ml. [online]. Dostupné z: http: //www.sukl.cz/modules/medication/detail.php?code=0139065&tab=texts

9. SPC – Hylase „Dessau“ 150 IU. [online]. Dostupné z: https: //www.google.com/search?q=Hylase+Dessau+SPC&rlz=1C1GCEU_csCZ894CZ894&oq=hylase&aqs=chrome.0.69i59j69i57j0l3j69i60l3.3518j0j7&sourceid=chrome&ie=UTF-8

10. SPC – Cyrdanax 20mg/ml inf plv 1x 500mg. [online]. Dostupné z: http: //www.sukl.cz/modules/medication/detail.php?code=0199360&tab=texts.